GEM-Derived Syngeneic Models
GEM-derived syngeneic models represent a significant advancement in preclinical cancer research, offering a powerful platform for studying tumor biology, rare diseases, and immunotherapy interventions. Our Company is dedicated to supporting researchers in their utilization of GEM-derived syngeneic models through our comprehensive range of services. With state-of-the-art facilities, a skilled team of experts, and a commitment to scientific excellence, we strive to provide reliable and high-quality services to accelerate rare disease drug discovery and development.
Introduction to GEM-Derived Syngeneic Models
The GEM-derived syngeneic model is also called the GEM-derived allograft (GDA) model, which combines the strengths of both GEM models and syngeneic models to provide a robust and versatile platform for preclinical cancer research. GEM models are created by introducing specific genetic modifications into mice to simulate human tumor development, while syngeneic models involve implanting mouse cancer cell lines into immunocompetent mice of the same strain. GEM-derived syngeneic models are constructed by transplanting tumor tissue fragments derived from GEM models into syngeneic hosts for growth and study.
Fig.1 Model selection for different study types. (Sobczuk P., et al., 2020)Advantages of GEM-Derived Syngeneic Models
GEM-derived syngeneic models offer several advantages over traditional mouse models, making them a valuable tool in preclinical rare cancer research.
- Providing an immunocompetent environment, allowing for the evaluation of immunotherapies and their effects on the tumor microenvironment.
- Observing and simulating tumor development, recurrence and metastasis in situ, simulating clinical scenarios. This advantage is particularly valuable in understanding the complex dynamics of tumor progression and testing interventions targeted at different stages of the disease.
- Overcoming the time-consuming tumor formation process associated with GEM models, enabling researchers to conduct studies with reduced timelines and improved consistency.
Our Services
At our company, we recognize the importance of cutting-edge mouse models in preclinical research. We offer a comprehensive range of services related to GEM-derived syngeneic models to support drug safety evaluation and pharmacokinetics research. Use these models to help you gain a deeper understanding of rare disease mechanisms, identify new research targets, and accelerate the development of innovative drugs.
Gene Editing / Modification
Isolate Tumor
Label with Imageable Markers
GEM-Derived Syngeneic Models
Optional typical GEM-derived syngeneic models include but are limited to:
- KRAS Mutation Syngeneic Model
- PTEN Mutation Syngeneic Model
- MMTV-PyVT TG Mutation Syngeneic Model
- IgH-Myc TG (Eμ Myc) Mutation Syngeneic Model
- APC Mutation Syngeneic Model
- KMT2C Mutation Syngeneic Model
- BRAF Mutation Syngeneic Model
- ARID1A Mutation Syngeneic Model
- FAT1 Mutation Syngeneic Model
- ATM Mutation Syngeneic Model
- ZFHX3 Mutation Syngeneic Model
- CREBBP Mutation Syngeneic Model
- GRIN2A Mutation Syngeneic Model
- NF1 Mutation Syngeneic Model
- TP53 Mutation Syngeneic Model
- PIK3CA Mutation Syngeneic Model
- LRP1B Mutation Syngeneic Model
- FAT4 Mutation Syngeneic Model
- KMT2D Mutation Syngeneic Model
- TRRAP Mutation Syngeneic Model
- PDE4DIP Mutation Syngeneic Model
- PTPRT Mutation Syngeneic Model
- RNF213 Mutation Syngeneic Model
- PREX2 Mutation Syngeneic Model
- SPEN Mutation Syngeneic Model
- KMT2A Mutation Syngeneic Model
- ERBB4 Mutation Syngeneic Model
Our Advantages
With a highly skilled research team boasting extensive expertise in GEM-derived syngeneic model development and access to an advanced platform, our company is well-positioned to offer exceptional GEM-derived syngeneic model development services for rare diseases. We pride ourselves on delivering tailored and personalized solutions and designing customized analysis processes that align with your unique scientific research requirements. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Sobczuk P., et al. "Choosing the right animal model for renal cancer research." Translational oncology 13.3 (2020): 100745.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.